S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
Log in
(Ad)
Income expert Neil George has just released a new book called Income for Life. Inside, it details more than 65 little-known income streams that ANYONE can collect However, this book is not available for sale. Instead, we're on a nationwide campaign to spread the book far and wide for FREE.

NASDAQ:ACHN - Achillion Pharmaceuticals Stock Price, Forecast & News

$6.11
-0.11 (-1.77 %)
(As of 01/22/2020 04:00 PM ET)
Today's Range
$6.10
Now: $6.11
$6.23
50-Day Range
$6.03
MA: $6.15
$6.31
52-Week Range
$2.06
Now: $6.11
$6.46
Volume2.00 million shs
Average Volume2.30 million shs
Market Capitalization$855.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59
Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ACHN
CUSIP00448Q20
Phone203-624-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.92 per share

Profitability

Net Income$-70,270,000.00

Miscellaneous

Employees56
Market Cap$855.69 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive ACHN News and Ratings via Email

Sign-up to receive the latest news and ratings for ACHN and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Located just 25 miles from Cleveland... is a supergreenhouse unlike anything we've ever seen. Listed at over 1.4 million sq ft, (the size of 9 full-sized Costco warehouses), this marijuana grow house is capable of producing over 341,000 pounds of weed/year! And very soon it will come online and could turn a tiny 60-cent pot company into the dominator in the white-hot weed market.

Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions

What is Achillion Pharmaceuticals' stock symbol?

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) released its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the Zacks' consensus estimate of ($0.16) by $0.02. View Achillion Pharmaceuticals' Earnings History.

When is Achillion Pharmaceuticals' next earnings date?

Achillion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Achillion Pharmaceuticals.

What price target have analysts set for ACHN?

5 Wall Street analysts have issued 1-year target prices for Achillion Pharmaceuticals' stock. Their forecasts range from $2.50 to $6.30. On average, they anticipate Achillion Pharmaceuticals' stock price to reach $5.03 in the next twelve months. This suggests that the stock has a possible downside of 17.6%. View Analyst Price Targets for Achillion Pharmaceuticals.

What is the consensus analysts' recommendation for Achillion Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achillion Pharmaceuticals.

Has Achillion Pharmaceuticals been receiving favorable news coverage?

Press coverage about ACHN stock has been trending somewhat positive on Wednesday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Achillion Pharmaceuticals earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Achillion Pharmaceuticals.

Are investors shorting Achillion Pharmaceuticals?

Achillion Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 14,080,000 shares, an increase of 11.0% from the December 15th total of 12,680,000 shares. Based on an average trading volume of 3,130,000 shares, the short-interest ratio is presently 4.5 days. Approximately 10.3% of the company's stock are short sold. View Achillion Pharmaceuticals' Current Options Chain.

Who are some of Achillion Pharmaceuticals' key competitors?

What other stocks do shareholders of Achillion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achillion Pharmaceuticals investors own include Chesapeake Energy (CHK), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NE), Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD), Celldex Therapeutics (CLDX), Iconix Brand Group (ICON), ACADIA Pharmaceuticals (ACAD) and Edap Tms (EDAP).

Who are Achillion Pharmaceuticals' key executives?

Achillion Pharmaceuticals' management team includes the folowing people:
  • Mr. Joseph Truitt, Pres, CEO & Director (Age 54)
  • Ms. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 64)
  • Mr. Brian R. Di Donato, CFO, SVP & Treasurer (Age 52)
  • Mr. Paul Firuta, Exec. VP & COO (Age 53)
  • Dr. Kevin P. Malobisky, Sr. VP of Regulatory Affairs, Quality & Compliance

Who are Achillion Pharmaceuticals' major shareholders?

Achillion Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Achillion Pharmaceuticals stock include David Scheer and Joseph Truitt. View Institutional Ownership Trends for Achillion Pharmaceuticals.

Which major investors are buying Achillion Pharmaceuticals stock?

ACHN stock was bought by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Achillion Pharmaceuticals.

How do I buy shares of Achillion Pharmaceuticals?

Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Achillion Pharmaceuticals' stock price today?

One share of ACHN stock can currently be purchased for approximately $6.11.

How big of a company is Achillion Pharmaceuticals?

Achillion Pharmaceuticals has a market capitalization of $855.69 million. The biopharmaceutical company earns $-70,270,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Achillion Pharmaceuticals employs 56 workers across the globe.View Additional Information About Achillion Pharmaceuticals.

What is Achillion Pharmaceuticals' official website?

The official website for Achillion Pharmaceuticals is http://www.achillion.com/.

How can I contact Achillion Pharmaceuticals?

Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.


MarketBeat Community Rating for Achillion Pharmaceuticals (NASDAQ ACHN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  484 (Vote Outperform)
Underperform Votes:  431 (Vote Underperform)
Total Votes:  915
MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACHN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Featured Article: The risks of owning bonds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel